Skip to main content

Anaptysbio, Inc 10-Q for FY2027 Q1

Anaptysbio, Inc (ANAB)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 13, 2026

About this 10-Q

Anaptysbio, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2027 Q1).

AnaptysBio reported $30.3 million in collaboration revenue for the three months ended September 30, 2026, down from $76.3 million, while Jemperli received accelerated FDA approval for previously untreated stage II and III dMMR/MSI-H locally advanced rectal cancer. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$30.27M
down 60.3% from $76.32M a year earlier
Net income
$3.88M
down 74.4% from net income of $15.11M a year earlier
Diluted EPS
$0.11
down 78.8% from $0.52 a year earlier